| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 31 | 2021 | 1677 | 2.540 |
Why?
|
| Neoplasms | 35 | 2024 | 2766 | 2.180 |
Why?
|
| Leukemia | 10 | 2019 | 376 | 1.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1230 | 0.920 |
Why?
|
| Pyrimidines | 6 | 2024 | 374 | 0.850 |
Why?
|
| Thalidomide | 3 | 2011 | 36 | 0.800 |
Why?
|
| Neuroblastoma | 7 | 2021 | 509 | 0.780 |
Why?
|
| Arabinonucleosides | 3 | 2006 | 32 | 0.770 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2021 | 522 | 0.750 |
Why?
|
| Azepines | 3 | 2019 | 61 | 0.690 |
Why?
|
| Medical Oncology | 4 | 2010 | 214 | 0.690 |
Why?
|
| Vincristine | 2 | 2021 | 195 | 0.650 |
Why?
|
| Meningeal Neoplasms | 7 | 2011 | 177 | 0.650 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2024 | 1115 | 0.640 |
Why?
|
| Maximum Tolerated Dose | 14 | 2024 | 157 | 0.570 |
Why?
|
| Child | 50 | 2024 | 24223 | 0.560 |
Why?
|
| Salvage Therapy | 5 | 2019 | 193 | 0.550 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2010 | 99 | 0.550 |
Why?
|
| Child, Preschool | 38 | 2024 | 13880 | 0.540 |
Why?
|
| Drug Therapy | 1 | 2016 | 87 | 0.530 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2015 | 102 | 0.530 |
Why?
|
| Piperazines | 4 | 2024 | 231 | 0.520 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 80 | 0.520 |
Why?
|
| Drugs, Essential | 3 | 2023 | 7 | 0.510 |
Why?
|
| Benzimidazoles | 2 | 2022 | 128 | 0.500 |
Why?
|
| Macaca mulatta | 12 | 2011 | 494 | 0.500 |
Why?
|
| Dacarbazine | 3 | 2011 | 86 | 0.490 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2024 | 194 | 0.480 |
Why?
|
| Oxygenases | 1 | 2014 | 4 | 0.480 |
Why?
|
| Daunorubicin | 1 | 2014 | 27 | 0.470 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2012 | 74 | 0.470 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2014 | 25 | 0.470 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 3 | 2009 | 20 | 0.470 |
Why?
|
| Adolescent | 39 | 2024 | 19095 | 0.460 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 128 | 0.460 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 243 | 0.460 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2020 | 804 | 0.450 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 280 | 0.440 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2024 | 714 | 0.440 |
Why?
|
| Area Under Curve | 12 | 2021 | 312 | 0.430 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2014 | 127 | 0.430 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2010 | 57 | 0.430 |
Why?
|
| Young Adult | 21 | 2024 | 8865 | 0.400 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 56 | 0.400 |
Why?
|
| Guanine | 3 | 2011 | 60 | 0.400 |
Why?
|
| Camptothecin | 3 | 2008 | 76 | 0.400 |
Why?
|
| Enzyme Inhibitors | 5 | 2009 | 571 | 0.390 |
Why?
|
| Sarcoma, Ewing | 3 | 2022 | 113 | 0.390 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 28 | 0.390 |
Why?
|
| Doxorubicin | 2 | 2014 | 301 | 0.380 |
Why?
|
| Informed Consent | 3 | 2009 | 342 | 0.380 |
Why?
|
| Patient Participation | 3 | 2010 | 220 | 0.360 |
Why?
|
| Humans | 68 | 2024 | 123152 | 0.360 |
Why?
|
| Male | 49 | 2024 | 60038 | 0.360 |
Why?
|
| Body Composition | 2 | 2014 | 513 | 0.350 |
Why?
|
| Obesity | 2 | 2014 | 2226 | 0.350 |
Why?
|
| Metabolic Clearance Rate | 5 | 2014 | 141 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2018 | 1682 | 0.350 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2010 | 137 | 0.330 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2020 | 178 | 0.330 |
Why?
|
| Chromatography, High Pressure Liquid | 8 | 2011 | 333 | 0.320 |
Why?
|
| Carboxylic Acids | 1 | 2008 | 24 | 0.320 |
Why?
|
| Rhabdomyosarcoma | 2 | 2022 | 200 | 0.320 |
Why?
|
| Infant | 21 | 2024 | 12339 | 0.320 |
Why?
|
| Boronic Acids | 2 | 2005 | 48 | 0.310 |
Why?
|
| Medulloblastoma | 2 | 2012 | 338 | 0.310 |
Why?
|
| Cyclophosphamide | 2 | 2008 | 420 | 0.310 |
Why?
|
| Physician-Patient Relations | 2 | 2009 | 426 | 0.310 |
Why?
|
| Pyrazines | 2 | 2005 | 73 | 0.310 |
Why?
|
| Oligopeptides | 1 | 2008 | 118 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2024 | 38 | 0.290 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2024 | 54 | 0.290 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 1089 | 0.290 |
Why?
|
| Phthalazines | 2 | 2024 | 14 | 0.280 |
Why?
|
| Female | 42 | 2024 | 65442 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 2585 | 0.270 |
Why?
|
| Infusions, Intravenous | 8 | 2005 | 533 | 0.270 |
Why?
|
| Indoles | 2 | 2004 | 181 | 0.260 |
Why?
|
| Topotecan | 3 | 2012 | 49 | 0.250 |
Why?
|
| Leukemia, T-Cell | 1 | 2005 | 12 | 0.250 |
Why?
|
| Ethics, Medical | 2 | 2007 | 396 | 0.250 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 95 | 0.250 |
Why?
|
| DNA Repair | 3 | 2024 | 581 | 0.240 |
Why?
|
| Cell Line, Tumor | 6 | 2018 | 3277 | 0.240 |
Why?
|
| Cyclopentanes | 1 | 2024 | 20 | 0.230 |
Why?
|
| Cyclin D1 | 1 | 2004 | 111 | 0.230 |
Why?
|
| Depsipeptides | 1 | 2004 | 10 | 0.230 |
Why?
|
| Cyclins | 1 | 2004 | 101 | 0.230 |
Why?
|
| Carbazoles | 1 | 2004 | 31 | 0.230 |
Why?
|
| Cisplatin | 2 | 2004 | 242 | 0.230 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 52 | 0.230 |
Why?
|
| Rhabdoid Tumor | 1 | 2023 | 49 | 0.220 |
Why?
|
| Parents | 3 | 2009 | 1023 | 0.220 |
Why?
|
| Glioma | 2 | 2022 | 491 | 0.210 |
Why?
|
| Methotrexate | 2 | 2020 | 341 | 0.210 |
Why?
|
| Pyridines | 1 | 2024 | 224 | 0.210 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2024 | 164 | 0.210 |
Why?
|
| Adult | 19 | 2024 | 29032 | 0.200 |
Why?
|
| Models, Theoretical | 1 | 2004 | 357 | 0.200 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2024 | 428 | 0.190 |
Why?
|
| Treatment Outcome | 14 | 2020 | 12116 | 0.190 |
Why?
|
| Dactinomycin | 1 | 2021 | 67 | 0.190 |
Why?
|
| Injections, Spinal | 6 | 2011 | 115 | 0.180 |
Why?
|
| Maytansine | 1 | 2020 | 3 | 0.180 |
Why?
|
| Neurofibrosarcoma | 1 | 2020 | 5 | 0.180 |
Why?
|
| Pulmonary Blastoma | 1 | 2020 | 11 | 0.180 |
Why?
|
| Sarcoma, Synovial | 1 | 2020 | 21 | 0.180 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 52 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2019 | 213 | 0.170 |
Why?
|
| Drug Synergism | 3 | 2009 | 240 | 0.170 |
Why?
|
| Drug Interactions | 3 | 2012 | 254 | 0.170 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2024 | 28 | 0.170 |
Why?
|
| Wilms Tumor | 1 | 2020 | 112 | 0.160 |
Why?
|
| Cerebrospinal Fluid | 3 | 2004 | 92 | 0.160 |
Why?
|
| Research Subjects | 1 | 2019 | 56 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 101 | 0.160 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 730 | 0.150 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 2011 | 16 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 162 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 1014 | 0.150 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 427 | 0.150 |
Why?
|
| Furans | 1 | 2018 | 27 | 0.150 |
Why?
|
| Research Personnel | 1 | 2019 | 118 | 0.150 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2014 | 75 | 0.150 |
Why?
|
| Ketones | 1 | 2018 | 24 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2023 | 594 | 0.150 |
Why?
|
| Aurora Kinase A | 1 | 2018 | 40 | 0.150 |
Why?
|
| Cell Cycle Proteins | 2 | 2019 | 647 | 0.150 |
Why?
|
| Recurrence | 3 | 2019 | 1422 | 0.150 |
Why?
|
| Animals | 16 | 2019 | 33720 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2020 | 293 | 0.140 |
Why?
|
| Cell Survival | 2 | 2012 | 803 | 0.140 |
Why?
|
| Health Policy | 1 | 2019 | 213 | 0.140 |
Why?
|
| Mass Spectrometry | 3 | 2006 | 326 | 0.130 |
Why?
|
| Brain Neoplasms | 2 | 2004 | 1217 | 0.130 |
Why?
|
| Health Care Rationing | 1 | 2016 | 58 | 0.130 |
Why?
|
| Palliative Care | 1 | 2019 | 428 | 0.120 |
Why?
|
| Pediatrics | 3 | 2010 | 1139 | 0.120 |
Why?
|
| Deoxycytidine | 2 | 2007 | 75 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 2 | 2022 | 352 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 94 | 0.120 |
Why?
|
| Prodrugs | 2 | 2006 | 59 | 0.120 |
Why?
|
| Glioblastoma | 1 | 2018 | 333 | 0.110 |
Why?
|
| Absorptiometry, Photon | 1 | 2014 | 178 | 0.110 |
Why?
|
| Separase | 1 | 2014 | 29 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 266 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2019 | 519 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 61 | 0.110 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 183 | 0.110 |
Why?
|
| Mutation | 2 | 2024 | 5773 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2005 | 1062 | 0.110 |
Why?
|
| Neoplasm Staging | 2 | 2008 | 1213 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1259 | 0.110 |
Why?
|
| Injections, Intravenous | 3 | 2008 | 252 | 0.110 |
Why?
|
| Meningitis, Aseptic | 1 | 2012 | 14 | 0.100 |
Why?
|
| Haplotypes | 1 | 2014 | 519 | 0.100 |
Why?
|
| Aurora Kinase B | 1 | 2012 | 8 | 0.100 |
Why?
|
| Aurora Kinases | 1 | 2012 | 31 | 0.100 |
Why?
|
| Pyrroles | 2 | 2024 | 178 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2024 | 206 | 0.100 |
Why?
|
| Survival Rate | 4 | 2019 | 1993 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2014 | 474 | 0.100 |
Why?
|
| Genomics | 1 | 2019 | 1477 | 0.100 |
Why?
|
| Brain Stem Neoplasms | 1 | 2011 | 39 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1580 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 809 | 0.090 |
Why?
|
| Half-Life | 4 | 2021 | 156 | 0.090 |
Why?
|
| Prognosis | 4 | 2019 | 4505 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2010 | 29 | 0.090 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 141 | 0.090 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 4268 | 0.090 |
Why?
|
| United States | 6 | 2024 | 10629 | 0.090 |
Why?
|
| Altruism | 1 | 2010 | 26 | 0.090 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 203 | 0.080 |
Why?
|
| DNA Mismatch Repair | 1 | 2009 | 48 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2020 | 1469 | 0.080 |
Why?
|
| Apoptosis | 3 | 2018 | 1780 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2010 | 171 | 0.080 |
Why?
|
| Tissue Distribution | 2 | 2019 | 382 | 0.080 |
Why?
|
| Acyclovir | 1 | 2008 | 45 | 0.080 |
Why?
|
| Bortezomib | 2 | 2005 | 73 | 0.080 |
Why?
|
| Valine | 1 | 2008 | 105 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2014 | 1541 | 0.080 |
Why?
|
| Carmustine | 1 | 2008 | 26 | 0.080 |
Why?
|
| Confidentiality | 1 | 2008 | 103 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 5046 | 0.070 |
Why?
|
| Human Experimentation | 1 | 2007 | 38 | 0.070 |
Why?
|
| Ethics, Research | 1 | 2007 | 50 | 0.070 |
Why?
|
| Carboplatin | 2 | 2004 | 75 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1641 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2007 | 101 | 0.070 |
Why?
|
| Administration, Intravenous | 2 | 2020 | 143 | 0.070 |
Why?
|
| DNA Damage | 2 | 2024 | 506 | 0.070 |
Why?
|
| Benzamides | 2 | 2023 | 107 | 0.070 |
Why?
|
| Valproic Acid | 1 | 2007 | 165 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 300 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 79 | 0.070 |
Why?
|
| Adenine Nucleotides | 1 | 2005 | 41 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 876 | 0.060 |
Why?
|
| Administration, Oral | 3 | 2018 | 671 | 0.060 |
Why?
|
| Risk | 1 | 2007 | 749 | 0.060 |
Why?
|
| Imidazoles | 1 | 2006 | 199 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 172 | 0.060 |
Why?
|
| Cyclin D3 | 1 | 2004 | 10 | 0.060 |
Why?
|
| Cyclin D2 | 1 | 2004 | 14 | 0.060 |
Why?
|
| Cyclin D | 1 | 2024 | 6 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2004 | 60 | 0.060 |
Why?
|
| NEDD8 Protein | 1 | 2024 | 11 | 0.060 |
Why?
|
| Thiophenes | 1 | 2005 | 60 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 194 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 6028 | 0.060 |
Why?
|
| Retinoblastoma Protein | 1 | 2004 | 77 | 0.060 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 39 | 0.060 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 43 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2004 | 85 | 0.060 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 67 | 0.060 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2024 | 93 | 0.060 |
Why?
|
| Quinazolines | 1 | 2005 | 175 | 0.060 |
Why?
|
| Aminopyridines | 1 | 2024 | 53 | 0.060 |
Why?
|
| SMARCB1 Protein | 1 | 2023 | 32 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 669 | 0.060 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2023 | 57 | 0.050 |
Why?
|
| Anemia | 1 | 2007 | 339 | 0.050 |
Why?
|
| Phenylacetates | 1 | 2003 | 23 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2023 | 1265 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 30 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 45 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2024 | 340 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 315 | 0.050 |
Why?
|
| Physicians | 1 | 2009 | 584 | 0.050 |
Why?
|
| Glutamine | 1 | 2003 | 195 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 224 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 313 | 0.050 |
Why?
|
| Mixed Function Oxygenases | 1 | 2002 | 32 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 83 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2004 | 612 | 0.050 |
Why?
|
| Europe | 1 | 2023 | 375 | 0.050 |
Why?
|
| Phenytoin | 1 | 2002 | 63 | 0.050 |
Why?
|
| Lymphoma | 1 | 2005 | 322 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2024 | 2047 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 414 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 155 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 550 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 136 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2022 | 236 | 0.050 |
Why?
|
| CD56 Antigen | 1 | 2020 | 26 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1432 | 0.050 |
Why?
|
| Decision Making | 1 | 2006 | 650 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 8 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 3660 | 0.040 |
Why?
|
| DNA Repair Enzymes | 2 | 2011 | 40 | 0.040 |
Why?
|
| DNA Modification Methylases | 2 | 2011 | 43 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 40 | 0.040 |
Why?
|
| Drugs, Generic | 1 | 2019 | 13 | 0.040 |
Why?
|
| Community Participation | 1 | 2019 | 44 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 290 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 88 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2002 | 370 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2005 | 3329 | 0.040 |
Why?
|
| Patient Rights | 1 | 2019 | 50 | 0.040 |
Why?
|
| Focus Groups | 1 | 2019 | 200 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 1240 | 0.040 |
Why?
|
| Family | 2 | 2016 | 579 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 113 | 0.040 |
Why?
|
| Algorithms | 1 | 2005 | 1595 | 0.040 |
Why?
|
| Microtubules | 1 | 2018 | 197 | 0.040 |
Why?
|
| Time Factors | 2 | 2004 | 6204 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2019 | 303 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2018 | 330 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 267 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2011 | 467 | 0.030 |
Why?
|
| Dexamethasone | 2 | 2012 | 272 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 803 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 390 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 149 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 134 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2011 | 1305 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1387 | 0.030 |
Why?
|
| Rhodamines | 1 | 2014 | 22 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1683 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2017 | 8103 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2014 | 155 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2023 | 2585 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 96 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 368 | 0.030 |
Why?
|
| Infusions, Intraventricular | 1 | 2012 | 12 | 0.030 |
Why?
|
| Mice | 3 | 2019 | 17486 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 330 | 0.030 |
Why?
|
| Antibodies | 1 | 2014 | 370 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2020 | 15998 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2014 | 399 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 113 | 0.020 |
Why?
|
| Age Factors | 2 | 2008 | 2799 | 0.020 |
Why?
|
| Peptides | 1 | 2014 | 796 | 0.020 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2008 | 19 | 0.020 |
Why?
|
| State Government | 1 | 2008 | 30 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 2942 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1004 | 0.020 |
Why?
|
| Government Regulation | 1 | 2008 | 43 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 1149 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2007 | 14 | 0.020 |
Why?
|
| Pharmacokinetics | 1 | 2007 | 16 | 0.020 |
Why?
|
| Microsatellite Instability | 1 | 2007 | 36 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2008 | 185 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 2008 | 39 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 300 | 0.020 |
Why?
|
| Hematinics | 1 | 2007 | 56 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2006 | 54 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2307 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 238 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2007 | 300 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 255 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2004 | 7 | 0.020 |
Why?
|
| Middle Aged | 3 | 2014 | 25966 | 0.020 |
Why?
|
| Biological Availability | 1 | 2004 | 128 | 0.010 |
Why?
|
| Meningitis | 1 | 2005 | 99 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2004 | 45 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 322 | 0.010 |
Why?
|
| Biotransformation | 1 | 2003 | 49 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2003 | 44 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2004 | 204 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 155 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 710 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 2002 | 65 | 0.010 |
Why?
|
| Ondansetron | 1 | 2002 | 10 | 0.010 |
Why?
|
| Pineal Gland | 1 | 2002 | 17 | 0.010 |
Why?
|
| Pinealoma | 1 | 2002 | 19 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 752 | 0.010 |
Why?
|
| Melphalan | 1 | 2002 | 49 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 714 | 0.010 |
Why?
|
| Phenobarbital | 1 | 2002 | 36 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 103 | 0.010 |
Why?
|
| Etoposide | 1 | 2002 | 117 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 2486 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2002 | 59 | 0.010 |
Why?
|
| Cranial Irradiation | 1 | 2002 | 69 | 0.010 |
Why?
|
| Pregnancy | 1 | 2014 | 7137 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 1416 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1743 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 4704 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 1442 | 0.010 |
Why?
|
| Seizures | 1 | 2002 | 871 | 0.010 |
Why?
|
| Disease Progression | 1 | 2002 | 2023 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2002 | 1196 | 0.010 |
Why?
|